AstraZeneca said the safety and tolerability profile for Truqap was consistent with other trials. This is another blow for one of AstraZeneca’s flagship oncology products, which failed to meet ...

AstraZeneca (NASDAQ:AZN) said on Tuesday it will discontinue its late stage trial testing Truqap combination in patients with metastatic castration-resistant prostate cancer following Independent ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its ...

AstraZeneca's Truqap is the first AKT inhibitor to win an FDA nod. But a biomarker restriction from the FDA came as a surprise. After the landmark success of Enhertu in HER2-low breast cancer, ...

AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients ...

AstraZeneca had a disappointing trial readout with its AKT inhibitor Truqap in breast cancer in June, so unsurprisingly it is trumpeting a first-in-class win for the drug in prostate cancer.

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.

Seven of the 355 recipients of Truqap in a phase 3 trial had grade 3 hyperglycemia, resulting in a frequency of 2%. One-third of patients in a Piqray study had (PDF) a grade 3 or worse reaction.

AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a new targeted therapy option that significantly increases ...

AstraZeneca’s (AZ) AKT inhibitor Truqap (capivasertib) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for advanced breast ...

High-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s (AZN) Truqap in combination with abiraterone and androgen deprivation therapy, ADT, demonstrated a ...